Evidence map›Paper›PMID 37652710›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

Dermal Exposure to Vesicating Nettle Agent Phosgene Oxime: Clinically Relevant Biomarkers and Skin Injury Progression in Murine Models.

Dinesh G Goswami, Satyendra K Singh, Ebenezar O M Okoyeocha, Andrew K Roney, Omid Madadgar, Rick Tuttle, William Sosna, Poojya Anantharam, Claire R Croutch, Rajesh Agarwal and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Dinesh G GoswamiDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Satyendra K SinghDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Ebenezar O M OkoyeochaDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Andrew K RoneyDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Omid MadadgarDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Rick TuttleDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
William SosnaDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Poojya AnantharamDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Claire R CroutchDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).
Rajesh AgarwalDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.).ORCID https://orcid.org/0000-0002-9455-0235
Neera Tewari-SinghDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine (D.G.G., E.O.M.O., A.K.R., O.M., N.T.-S.) and Department of Biomedical Engineering (S.K.S.), Michigan State University, East Lansing, Michigan; MRIGlobal, Kansas City, Missouri (R.T., W.S., P.A., C.R.C.); and Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (R.A.) tewarisi@msu.edu.ORCID https://orcid.org/0000-0002-0353-4425
Michigan State University · USMRIGlobal · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin ExposureU01AR075470 · NIAMS · MICHIGAN STATE UNIVERSITY · PI TEWARI-SINGH, NEERA · 2019 to 2021
$1.4M
Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic TargetsR21AR073544 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI TEWARI-SINGH, NEERA · 2017 to 2018
$487k
NIAMS NIH HHS R21 AR073544NIAMS NIH HHS U01 AR075470
6 · The paper itself

Abstract

Phosgene oxime (CX), categorized as a vesicating chemical threat agent, causes effects that resemble an urticant or nettle agent. CX is an emerging potential threat agent that can be deployed alone or with other chemical threat agents to enhance their toxic effects. Studies on CX-induced skin toxicity, injury progression, and related biomarkers are largely unknown. To study the physiologic changes, skin clinical lesions and their progression, skin exposure of SKH-1 and C57BL/6 mice was carried out with vapor from 10

Indexed as

Chemical Warfare AgentsMustard GasPhosgeneAnimalsBiomarkersDisease Models, AnimalErythemaIrritantsMiceMice, Inbred C57BLOximesSkinBiomarkersChemical Warfare AgentsIrritantsMustard GasOximesPhosgene

Identifiers

PMID37652710
PMCPMC10801780
OpenAlexW4386315818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.